Login
Companies $SENS
$11.05 +$0.15 (1.38%) After hours
Senseonics Holdings, Inc. logo

Senseonics Holdings, Inc.

senseonics.com

What Do They Do?

Sells implantable glucose monitors for people with diabetes and their healthcare providers.

How Do They Make Money?

Distributors and strategic fulfillment partners buy Eversense systems and components, with sales counted when delivery terms are met; under consignment, sales count when a patient uses the product.

FY2025 revenue

Who Are Their Customers?

Senseonics sells mainly to distributors and strategic fulfillment partners, which provide Eversense to healthcare providers and patients after a prescription and bill insurance payors. It also supplies products on consignment through healthcare professionals.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2024: 82% from one customer

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +142%
vs $8.1M in Q3 FY2025
Net income
▼ −67% (Loss)
vs −$19.5M in Q3 FY2025
  • Nov 9, 2026 Raised full-year revenue guidance The company raised its 2026 revenue range to $68 million to $70 million from $62 million to $66 million.
  • Jun 1, 2026 Completed purchase of European Eversense commercial assets The German, Spanish and Swedish purchases closed June 1, 2026; the Italian purchase closed June 8, 2026.
  • Mar 12, 2026 Agreed to acquire European Eversense commercial assets The agreements cover commercial assets in Italy, Germany, Spain and Sweden, with purchases subject to closing conditions.

Growing. Revenue grew 2.6x in 4 years, from $13.7M in FY2021 to $35.3M in FY2025, about 27% a year.

Commercial operations Senseonics has moved from relying on Ascensia for exclusive worldwide distribution and commercial work to taking over U.S. marketing and sales, while Ascensia's European role has become non-exclusive.

Longer-lasting product The product range has expanded from earlier Eversense systems to a longer-lasting implantable monitor that has moved from development into commercial sale.

Who Do They Compete With?

Competes with Dexcom, Medtronic, Abbott, Roche Diagnostics, and Ascensia

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support